Study ID | Study design | Participant | Sample size (male/female) | Intervention | Dosage | Duration | Generation | Adverse event |
---|---|---|---|---|---|---|---|---|
West AL 2019 [97] | Double-blind crossover trial | Male younger participants (18 to 30Â years) | 10 | 450Â mg eicosapentaenoic plus decosahexaenoic from either 455Â mg transgenic Camelina sativa seed oil (CSO) or 452Â mg commercial blended fish oil (BFO) in test meal (a milkshake drink, and toast and jam) | 455Â mg CSO or 452Â mg BFO in the test meal | 2 single breakfast with at least 14Â days apart | 1 | No specific oil-related minor illness and no test oil-related consequences. No major adverse symptoms or health effects. The minor illness was as follows: 1. 2 cases of minor upper respiratory tract infections (a cold and tonsillitis) out of the seventy-two postprandial sessions* (2 sessions for each of the 36 participants) 2. 1 case of minor nose bleed some hours after one postprandial session with a pre-existing non-clinical tendency towards this 3. 1 case of pyelonephritis between postprandial sessions which was fully resolved 4. 3 cases of headaches during both postprandial sessions |
 |  | Female younger participants (18 to 30 years) | 10 | |||||
 |  | Male older participants (50 to 65 years) | 6 |  |  |  | ||
 |  | Male older participants (50 to 65 years) | 10 |  |  |  |